目的:探索缬沙坦在原发性高血压临床治疗中的应用价值。方法:选取我院于2014年6月至2015年6月间收治的原发性高血压患者200例作为临床研究对象,将其随机分为观察组和对照组,每组各100例,给予对照组患者氢氯噻嗪片治疗,给予观察组患者缬沙坦治疗,对比分析两组患者治疗效果和临床不良反应发生情况。结果:经统计发现,在治疗前,两组患者在收缩压、舒张压、臂-踝脉搏波传导速以及踝臂指数方面无显著性差异(P>0.05)。治疗后,观察组患者臂-踝脉搏波传导速显著快于对照组患者(P<0.05),差异具有统计学意义。此外,治疗前后,两组患者的上述四项指标变化值显著(P<0.05),均具有统计学意义。结论:缬沙坦在治疗原发性高血压疾病方面表现出良好的耐受性,显著降低了患者血压以及不艮并发症的发病率,在临床买践中值得推广应用。 Objective: To explore the value of valsartan in the treatment of essential hypertension. Methods: A total of 200 patients with essential hypertension treated in our hospital from June 2014 to June 2015 were selected as clinical study subjects. They were randomly divided into observation group and control group with 100 cases in each group. Hydrochlorothiazide tablets were given to the patients in the observation group, valsartan was given to the observation group, and the treatment effect and the incidence of clinical adverse reactions were compared between the two groups. Results: Statistics showed that there was no significant difference in systolic blood pressure, diastolic blood pressure, arm-ankle pulse wave velocity and ankle-brachial index before treatment in both groups (P> 0.05). After treatment, arm-ankle pulse wave velocity in observation group was significantly faster than that in control group (P <0.05), and the difference was statistically significant. In addition, before and after treatment, the two groups of patients with significant changes in the above four indicators (P <0.05), were statistically significant. CONCLUSIONS: Valsartan shows good tolerability in the treatment of essential hypertension and significantly reduces the incidence of blood pressure and complications. It is worthy of promotion in clinical practice.